IP Verse

Prolonged Release Dosage Form Of Tapentadol L-(+)- Tartaric Acid Salt - EP3995135

The patent EP3995135 was granted to Grnenthal on Jul 13, 2022. The application was originally filed on Nov 10, 2020 under application number EP20206800A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3995135

GRNENTHAL
Application Number
EP20206800A
Filing Date
Nov 10, 2020
Status
Granted And Under Opposition
Jun 10, 2022
Grant Date
Jul 13, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZSep 30, 2022KRAUS & LEDERER PARTGMBBWITHDRAWN
INSUD PHARMA SLJul 13, 2022AERAWITHDRAWN

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0693475
DESCRIPTIONEP2942054
DESCRIPTIONWO03035053
DESCRIPTIONWO03035054
DESCRIPTIONWO2006002886
DESCRIPTIONWO2008051617
DESCRIPTIONWO2009092601
DESCRIPTIONWO2015014980
DESCRIPTIONWO2017085734
OPPOSITIONEP3656765
OPPOSITIONWO2006002886
OPPOSITIONWO2008051617
OPPOSITIONWO2008128739
OPPOSITIONWO2009092601
OPPOSITIONWO2017085734
SEARCHEP2942054
SEARCHUS2015283087
SEARCHWO2009092601
SEARCHWO2017085734

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- B. R. C. ROWE et al., Formulation and Analytical Development for Low-Dose Oral Drug Products, Pharmaceutical Press, (20090000), pages 150 - 155-
DESCRIPTION- "Developing Solid Oral Dosage Forms", Y. QIU et al., Pharmaceutical Theory & Practice, Elsevier, (20170000), pages 940 - 942-
DESCRIPTION- "Drug Product Design, Development, and Modeling", M.T. ENDE et al., Chemical Engineering In The Pharmaceutical Industry, Wiley, (20190000), pages 228 - 232-
DESCRIPTION- D.V. REDDY et al., Journal of Pharmacy Research, (20140000), vol. 8, no. 10, pages 1368 - 1374-
DESCRIPTION- L.L. AUGSBURGER et al., Pharmaceutical Dosage Forms: Tablets, informa healthcare, (20080000), pages 26 - 30-
DESCRIPTION- S.K. PARAMASIVAN et al., GSC Biological and Pharmaceutical Sciences, (20180000), vol. 04, no. 03, pages 042 - 048-
DESCRIPTION- S.M. AFZAL et al., Int J A PS BMS, (20170000), vol. 6, no. 1, pages 1 - 21-
DESCRIPTION- "Tablet Compression: Machine Theory, Design, and Process Troubleshooting", J. SWARBRICKM. BOGDA, Encylopedia of Pharmaceutical Technology, Informa Healthcare, (20070000), pages 3611 - 2629-
OPPOSITION- Anonymous, "Palexia® retard Retardtabletten", Grunenthal, (20170801), pages 1 - 6, Grunenthal, (20220726), XP055946155-
OPPOSITION- Anonymous, "Tartaric acid", European Pharmacopoeia, (20100715), page 3038, XP055946153-
OPPOSITION- Fda, "Nucynta® ER", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20191001), pages 1 - 35, HIGHLIGHTS OF PRESCRIBING INFORMATION, (20220726), XP055946159-
OPPOSITION- Ramu B, Ramakrishna M, Sathish Kumar Meruva, "Formulation and Evaluation of Monolithic Matrix Tablets of Zidovudine by using Natural Gums", International Journal of Pharma Sciences and Research (IJPSR), (20150601), vol. 6, no. 6, pages 948 - 957, XP055946162-
OPPOSITION- Rowe Raymond C, Sheskey Paul J, Marian E. Quinn, "Tartaric acid", Handbook of Pharmaceutical Excipients, PhP, (20090101), pages 732 - 733, XP055946152-
OPPOSITION- Stahl Heinrich P., Camile G. Wermuth, "Chapter 11: Selected Procedures for the preparation of Pharmaceutical AcceptableSalts", Handbook of Pharmaceutical Salts, (20020101), pages 249 - 258,265-310, XP055946151-
OPPOSITION- Stuchlik S., Mag J. Eberl, "Palexia® retard 50 mg-Retardtabletten", Gerot Lannach - Report of Analisys, (20191206), page 1, Gerot Lannach - Report of Analisys, (20220726), XP055946157-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents